Darunavir/ritonavir Reactions 1680, p114 - 2 Dec 2017 Sinus bradycardia: case report A 38-year-old woman developed sinus bradycardia during treatment with darunavir/ritonavir [dosage and route not stated]. The woman presented to the hospital with a complaint of worsening visual blurring in the previous 2 weeks. Her medical history included HIV-1 infection for 2 years. She was also diagnosed with cytomegalovirus (CMV) retinitis of the right eye on her previous hospitalisation and was treated with ganciclovir. She was also initiated on antiretroviral therapy including darunavir/ritonavir and emtricitabine/tenofovir. However, she was not taking the medications prior to the admission. Her vital signs were stable with a heart rate (HR) of 72 90 beats/min. She was hospitalised with a diagnosis of severe bilateral necrotising CMV retinitis. She was stated on foscarnet. She also received ganciclovir. She was restated on antiretroviral therapy with darunavir/ritonavir and opportunistic infection prophylaxis was continued with azithromycin and atovaquone for a history of sulfa allergy. She was stable until day 5 of hospital stay. On day 5 of treatment with darunavir/ritonavir, she developed episodes of bradycardia with HR of 50 60 beats/min. Her HR dropped further to 44 52 beats/min over the next 2 days. ECG revealed sinus bradycardia. Non-specific T-wave changes in the lateral leads were also noted, but were an old finding and remained stable compared to previous studies. Treatment with darunavir/ritonavir was discontinued and was switched to emtricitabine/tenofovir. Bradycardia resolved within 48 hours. She completed a 3-week course of foscarnet therapy with improvement of her vision. No additional episodes of bradycardia were observed. Author comment: "We present a case of transient sinus bradycardia induced by darunavir-ritonavir in a patient with HIV/AIDS." Gonzales Zamora JA, et al. Sinus bradycardia induced by darunavir-ritonavir in a patient with acquired immunodeficiency syndrome. Infection 45: 721-723, No. 5, Oct 2017. Available from: URL: http://doi.org/10.1007/s15010-017-1065-5 - USA 803284867 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial